文献速递类风湿关节炎脊柱关节炎

戈利木单抗治疗炎症性关节病四年随访:NOR-DMARD观察性多中心研究

Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study.
PubMed 文献 · Semin Arthritis Rheum · 2019-07-12

基于挪威NOR-DMARD前瞻性观察性多中心研究,纳入808例起始戈利木单抗治疗的患者(RA 163例、PsA 266例、ax-SpA 379例),比较bDMARD初治与非初治患者的药物生存率与疗效。结果显示1/2/4年药物生存率在初治与非初治患者间无显著差异,RA与PsA患者联用或不联用csDMARDs亦无显著差异;bDMARD初治ax-SpA患者3个月ASDAS/BASDAI/MHAQ应答更优。

要点

  • bDMARD初治与非初治RA、PsA、ax-SpA患者1/2/4年戈利木单抗药物生存率无显著差异。
  • RA与PsA患者联用或不联用csDMARDs的药物生存率无显著差异。
  • bDMARD初治ax-SpA患者3个月ASDAS/BASDAI/MHAQ应答显著优于非初治者。

核心结论

  • 戈利木单抗在bDMARD初治与非初治RA、PsA、ax-SpA患者间药物生存率无显著差异,联用csDMARDs与否亦无显著差异。
  • bDMARD初治ax-SpA患者3个月应答显著优于非初治者,RA和PsA初治者呈更优应答趋势。
  • 总体及PsA、ax-SpA亚组中患者总体评价与女性性别为4年停药预测因素,RA中为患者总体评价与CRP。

研究设计与样本

  • 挪威NOR-DMARD前瞻性观察性多中心研究,纳入808例起始戈利木单抗治疗的患者(RA 163例、PsA 266例、ax-SpA 379例)。
  • 药物生存率采用Kaplan-Meier分析及log rank检验,治疗应答比较采用ANCOVA,停药预测因素采用单因素和多因素Cox回归分析。

主要发现

  • 1/2/4年戈利木单抗药物生存率在bDMARD初治与非初治患者间无显著差异(总体p≥0.12;RA p≥0.07;PsA p≥0.28;ax-SpA p≥0.61)。
  • RA(p≥0.10)与PsA(p≥0.07)患者联用与不联用csDMARDs的药物生存率无显著差异。
  • bDMARD初治较非初治ax-SpA患者3个月ASDAS/BASDAI/MHAQ应答更优(p≤0.02);RA与PsA初治者呈更优应答趋势。
  • 4年戈利木单抗停药的预测因素:总体及PsA、ax-SpA亚组为患者总体评价与女性性别,RA为患者总体评价与CRP。

关键数值与推荐

  • bDMARD初治与非初治患者1/2/4年药物生存率差异检验:总体p≥0.12、RA p≥0.07、PsA p≥0.28、ax-SpA p≥0.61。
  • RA与PsA患者联用vs不联用csDMARDs药物生存率差异检验:RA p≥0.10、PsA p≥0.07。
  • bDMARD初治较非初治ax-SpA患者3个月ASDAS/BASDAI/MHAQ应答更优(p≤0.02)。

临床怎么用

  • 对于RA、PsA、ax-SpA患者,无论既往是否使用过bDMARD,戈利木单抗均可作为治疗选择,药物生存率无显著差异。
  • RA与PsA患者使用戈利木单抗时联用或不联用csDMARDs对药物生存率无显著影响,可个体化决定。
  • ax-SpA患者尽早(bDMARD初治阶段)启用戈利木单抗可能获得更优的3个月疾病活动度与功能应答。
  • 关注患者总体评价高、女性(总体及PsA、ax-SpA)及CRP升高(RA)等停药预测因素,加强随访。

局限性

  • 本研究为观察性研究,非随机对照设计,存在混杂因素可能。
  • 原文摘要未报告具体停药率数值、效应量及置信区间等详细数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare (1) golimumab drug survival and efficacy in bDMARD naïve compared with non-naïve rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (ax-SpA) patients, (2) golimumab drug survival in RA and PsA patients treated with/without concomitant csDMARDs, (3) predictors of golimumab drug discontinuation. METHODS: Patients starting golimumab were included from the prospective observational multicenter Norwegian DMARD study. Drug survival was explored by Kaplan-Meier analyses with log rank test. Treatment responses were compared using ANCOVA. Univariate and multivariate Cox regression analyses were performed to identify predictors of golimumab discontinuation. RESULTS: We included 808 patients (163 RA, 266 PsA, 379 ax-SpA). Golimumab drug survival after 1/2/4 years were not significantly different between bDMARD naïve and non-naïve patients (all, p ≥ 0.12; RA, p ≥ 0.07; PsA, p ≥ 0.28; ax-SpA, p ≥ 0.61), nor between RA (p ≥ 0.10) and PsA (p ≥ 0.07) patients treated with vs. without csDMARD comedication. bDMARD naïve compared with non-naïve ax-SpA patients had better 3-month ASDAS/BASDAI/MHAQ responses (p ≤ 0.02). bDMARD naïve compared with non-naïve RA and PsA patients had a trend towards better treatment responses. Identified predictors of 4-year golimumab discontinuation were patient's global and female gender in patients overall and in subgroups of PsA and ax-SpA patients, and patient's global and CRP in RA. CONCLUSION: Golimumab drug survival was not significantly different between bDMARD naïve and non-naïve RA, PsA and ax-SpA patients, nor between RA and PsA patients treated with vs. without concomitant csDMARDs. Treatment responses were significantly better for bDMARD naïve than non-naïve ax-SpA patients. Identified predictors of golimumab discontinuation were patient's global and female gender in patients overall and in subgroups of PsA and ax-SpA patients, and patient's global and CRP in RA.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Michelsen B, Sexton J, Wierød A, et al. Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study. Semin Arthritis Rheum. 2019. PMID: 31358361. doi:10.1016/j.semarthrit.2019.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。